As expected, high-risk individuals have a considerably higher somatic mutation burden, typically for the genes KARS and TP53, which are known to be the primary drivers of PAAD (Kleeff et al., 2016) (Figure 7E; Supplementary Figure S4A). This evidence concerns the gene KARS1 and pancreatic adenocarcinoma.